



**Nicolas Vuilleumier**

**Contact**

Nicolas Vuilleumier

## Publications (6)

Raptis C, Berger C, Ciurea A, Andrey D, Polysopoulos C, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Möller B, Vuilleumier N, Finckh A, Rubbert-Roth A. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. *Front Immunol* 2022; 13:1016927.

Schmiedeberg K, Abela I, Pikor N, Vuilleumier N, Schwarzmüller M, Epp S, Pagano S, Grabherr S, Patterson A, Nussberger M, Trkola A, Ludewig B, von Kempis J, Rubbert-Roth A. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. *RMD Open* 2022; 8

Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Rottländer Y, Pirker I, von Kempis J (2022). Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study.

Vuilleumier N, Pagano S, Ludewig B, Schmiedeberg K, Haller C, von Kempis J, Rubbert-Roth A. Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?. *Eur J Clin Invest* 2021; 52:e13713.

Schmiedeberg K, Vuilleumier N, Pagano S, Albrich W, Ludewig B, von Kempis J, Rubbert-Roth A. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. *Lancet Rheumatol* 2021; 4:e11-e13.

Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Haller C, von Kempis J. Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. *Lancet Rheumatol* 2021; 3:e470-e472.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)